A phase I/II study of atacicept (TACI-Ig) to neutralize APRIL and BLyS in patients with refractory or relapsed multiple myeloma (MM) or active previously treated waldenstrom's macroglobulinemia (WM).

被引：9
|
作者：
Rossi, Jean-Francois
Moreaux, Jerome
Rose, Mikaelle
Picard, Marie
Ythier, Arnaud
Rossier, Ciara
Sievers, Eric
Klein, Bernard
机构：
[1] Univ Hosp, Unit Cellular & Gene Therapy, Montpellier, France
[2] Serono Int, Geneva, Switzerland
[3] Zymogenet Inc, Seattle, WA 98105 USA
来源：
BLOOD | 2006年 / 108卷 / 11期
关键词：
D O I：
10.1182/blood.V108.11.3578.3578
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3578
引用
收藏
页码：1022A / 1022A
页数：1
相关论文
共 50 条
  • [31] A Phase I/II Study of the Combination of Panobinostat (PAN) and Carfilzomib (CFZ) in Patients (pts) with Relapsed or Relapsed/Refractory Multiple Myeloma (MM): Comparison of Two Expansion Cohorts
    Berdeja, Jesus G.
    Gregory, Tara B.
    Faber, Edward A.
    Matous, Jeffrey V.
    Hart, Lowell L.
    Mace, Joseph R.
    Peyton, James D.
    Essell, James H.
    Arrowsmith, Edward R.
    Flinn, Ian W.
    BLOOD, 2015, 126 (23)
  • [32] Lenalidomide, bortezomib, and dexamethasone (Rev/Vel/Dex) in patients with relapsed or relapsed/refractory multiple myeloma (MM): Preliminary results of a phase II study
    Richardson, Paul
    Jagannath, Sundaf
    Raje, Noopur
    Jakubowiak, Andrzej
    Lonial, Sagar
    Ghobrial, Irene
    Schlossman, Robert
    Mazumder, Amitabha
    Munshi, Nikhil
    Colson, Kathleen
    McKenney, Mary
    Farrell, Melissa
    Lunde, Laura
    Giove, Lawrence
    Kaster, Sarah
    Mitsiades, Constantine
    Hideshima, Teru
    Knight, Robert
    Esseltine, Dixie-Lee
    Anderson, Kenneth
    BLOOD, 2007, 110 (11) : 797A - 797A
  • [33] A phase II clinical study of arsenic trioxide (ATO) in patients(pts) with relapsed or refractory multiple myeloma (MM); a preliminary report
    Hussein, MA
    Mason, J
    Ravandi, F
    Rifkin, RM
    BLOOD, 2001, 98 (11) : 378A - 378A
  • [34] Arsenic trioxide (Trisenox®) in patients with relapsed or refractory multiple myeloma (MM):: Final report of a phase II clinical study.
    Hussein, MA
    Mason, J
    Saleh, MN
    Rifkin, RM
    Ravandi, F
    BLOOD, 2002, 100 (11) : 393B - 393B
  • [35] A phase I/II trial of VELCADETM and melphalan combination therapy (Vc plus M) for patients with relapsed or refractory multiple myeloma (MM).
    Yang, HH
    Swift, R
    Sadler, K
    Vescio, R
    Adams, J
    Schenkein, D
    Berenson, JR
    BLOOD, 2003, 102 (11) : 235A - 235A
  • [36] A phase I/II trial of melphalan (MEL) combined with panobinostat (PAN) for patients with relapsed or refractory (R/R) multiple myeloma (MM).
    Yellin, Ori
    Berenson, James R.
    Boccia, Ralph V.
    Cohn, Allen Lee
    Berard, Paul
    Ghazal, Hassan
    Jamshed, Saad
    Kingsley, Edwin
    Harb, Wael A.
    Noga, Stephen J.
    Nassir, Youram
    Swift, Regina A.
    Vescio, Robert A.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [37] A phase I/II study of idarubicin, dexamethasone and interferon-α (I-Dexa) in patients with relapsed or refractory multiple myeloma
    Hübel, K
    Tesch, H
    Kröger, B
    Schnell, R
    Borchmann, P
    Diehl, V
    Engert, A
    LEUKEMIA, 1997, 11 : S47 - S51
  • [38] A multicenter phase I/II trial of perifosine (KRX-0401) + bortezomib in relapsed and refractory multiple myeloma patients previously treated wth bortezomib: Preliminary results
    Richardson, P. G.
    Jakubowiak, A.
    Wolf, J.
    Krishnan, A.
    Lonial, S.
    Ghobrial, I.
    Facon, T.
    Colson, K.
    Kendall, T.
    Leister, C.
    Martineau, B.
    Hideshima, T.
    Sportelli, P.
    Birch, R.
    Henderson, I. C.
    Anderson, K.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 (06): : 155 - 156
  • [39] Phase I/II Results of a Multicenter Trial of Perifosine (KRX-0401) + Bortezomib in Patients with Relapsed or Relapsed/Refractory Multiple Myeloma Who Were Previously Relapsed from or Refractory to Bortezomib
    Richardson, Paul
    Wolf, Jeffrey
    Jakubowiak, Andrzej
    Zonder, Jeffrey
    Lonial, Sagar
    Irwin, David H.
    Densmore, John
    Krishnan, Amrita
    Raje, Noopur
    Bar, Michael H.
    Allerton, Jeffrey P.
    Schlossman, Robert
    Ghobrial, Irene M.
    Munshi, Nikhil C.
    Martin, Thomas
    Laubach, Jacob
    Colson, Kathy
    Dean, Sarah
    Tocco, Deanna
    Steinfield, Elizabeth
    Kendall, Tara
    O'Riley, Kimberly
    Hideshima, Teru
    Sportelli, Peter
    Gardner, Lesa
    Anderson, Kenneth C.
    BLOOD, 2008, 112 (11) : 321 - 322
  • [40] Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: A phase II study of the National Cancer Institute of Canada Clinical Trials Group
    Chen, Christine I.
    Kouroukis, C. Tom
    White, Darrell
    Voralia, Michael
    Stadtmauer, Edward
    Stewart, A. Keith
    Wright, John J.
    Powers, Jean
    Walsh, Wendy
    Eisenhauer, Elizabeth
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (12) : 1570 - 1575
12345